| Notes :-
1. Pursuant to the sanction of the Hon'ble High Court of Delhi, to the Scheme of Arrangement, the pharmaceutical undertaking of the company has been transferred to Dabur Pharma Limited with effective date of 02/12/2003,with retrospective date of 01/04/2003 ( Appointed Date). Dabur Pharma Limited had applied to Stock Exchanges for in principle listing approval which is expected shortly. Soon thereafter the company will fix the Record Date to ascertain the shareholders who will be entitled to receive shares of Dabur Pharma Limited, till then the shares of Dabur India Limited will be traded cum
Pharma.
2. Column 5,8 and 11 reflect pre demerger figures ( including Pharmaceutical business) as were presented in the corresponding results of the previous year. Consequent to note No. 1 above, we have recast the figures of previous year to reflect only the FMCG business of the company., which are shown in the column 4,7 and 10 to make these figures comparable with that of current year.
3. DIL Sales & PAT grew by 13.3% and 46.9% respectively for the IVth qtr ended on 31st March 2004.
4. DIL Sales & PAT grew by 9.5% and 40.6% respectively for the year ended on 31st March 2004.
5. Consolidated Sales & PAT grew by 12.0% and 37.0% respectively for the year ended on 31st March 2004, on like to like basis.
6. The company has provided deferred tax liability in accordance with Accounting Standard - 22.
7. None of the assets qualify for impairment in accordance with Accounting Standard - 28.
8. The newly set up manufacturing facilities for Shampoo at Baddi became operational during the IVth Quarter.
9. Of the total investment ,long term investment made by the Company are both strategic and non strategic. There is no decline in the market value of non strategic investments Remaining investments being strategically held, no provision has been deemed necessary in this connection under Accounting Standard 13.
10. Consolidated Financial Results comprise the performance of the parent / subsidiaries companies viz: (a) Dabur India Limited (b) Dabur Nepal Pvt. Ltd. ( c) Dabur Foods Ltd. (d) Dabur Egypt Ltd. (e) Dabur Overseas Ltd. (f) Pasadensa Foods Ltd. (g) Dabur International Ltd. (h) Weikfield International (UAE) Ltd. (i) Asian Consumercare Pvt. Ltd.
11. During the quarter , the entire investment in shares of Dabur Finance Ltd. has been sold. Consequently Dabur Finance Ltd. had ceased to be a subsidiary of the company.
12. Pursuant to the approval of the Board of Director of the company to demerge its Pharmaceuticals Business into a new entity w.e.f. 01/04/2003, the relevant subsidiaries which form part of the Pharmaceuticals Business have been excluded from the consolidated financial results as per para 11 of AS 21.
13. Information on investor complaints for the quarter in numbers: Opening: - NIL ,Received: - 23 , Disposed off:- 21 , and closing:- 2.(has since then been resolved)
14. The board has proposed the final dividend @ Rs. 1.40 (140%) per equity share (having face value of Rs. 1 each) for the year 2003-2004 aggregating to Rs. 40.07 crores (excluding Tax on Dividend), subject to shareholder's approval. The company has already paid the interim dividend @ Rs. 0.60 (60%) per equity share ( having face value of
Rs. 1 each) for the year 2003-2004 aggregating to Rs. 17.17 crores (excluding Tax on Dividend). With this, total dividend (Interim+Final) payout ratio aggregates to 56.6% (excluding tax on dividend).
15. Corresponding figures of previous year have been regrouped wherever considered necessary to correspond to current year classification.
16. The above results reviewed by the Audit Committee, have been taken on record by the Board of Directors in its meeting held on 5th May 2004.
|